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Naloxone inhibits renal hemodynamic effect of head-out water
immersion in humans
KARIN A. vi TILBORG, TON J. RABELINK, and HEIN A. KooMs
Department of Nephrology and Hypertension, University Hospital Utrecht, The Netherlands
Naloxone inhibits renal hemodynamic effect of head-out water immer-
sion in humans. Head-out water immersion (HOT) is followed by renal
vasodilation and natriuresis, in association with a fall in blood pressure.
The latter suggests an exaggerated sympathetic suppression. We studied
the role of endogenous opioids on the renal response to HOI. Six healthy
subjects underwent four- hour clearance studies during: (1) time control;
(2) naloxone 0.1 mg/kg iv. bolus, followed by 0.1 mg/kglhr; (3) HOT; and
(4) concomitant HOL and naloxone administration. Compared to the time
control study, naloxone had no effects on mean arterial pressure (MAP),
plasma renin activity (PRA), aldosterone, catecholamines, atrial natri-
uretic peptide (ANP), glomerular filtration rate (GFR), estimated renal
plasma flow (ERPF), and sodium excretion. HOT caused significant
decrements of MAP, PRA, aldosterone, and catecholamines, and in-
creased ANP, GFR, from 94 5 to T02 5 mI/mm (P < 0.01), ERPF,
from 529 30 to 616 35 mI/mm (P < 0.01), and sodium excretion.
Renal blood flow increased as well, and calculated renal vascular resis-
tance decreased from 99 6 to 77 5 mm Hg- mm liter (P < 0.OT).
HOT during concomitant naloxone administration had similar effects on
MAP and humoral factors, however, caused no change in GFR, ERPF and
renal blood flow, and the fall in renal vascular resistance, from 98 6 to
83 5 mm Hg mm liter (P < 0.05) was significantly less than found
in the absence of naloxone (P < 0.05). The natriuretic effect was
undisturbed. These data suggest that endogenous opioids play a role in the
response to HOT, in particular, potentiate the renal vasodilatory response.
We have recently shown that continued neck suction can cause
renal vasodilation in seated sodium-restricted healthy humans,
thereby stressing the separate role of the arterial baroreflex in the
neural control of renal function [1]. However, the actual neural
control of kidney function during volume challenges is complex,
involving the integration in the vasomotor center of the brain stem
of, among others, cardiopulmonary and arterial baroreflex activ-
ities [2], Head-out water immersion (HOI) causes an increase in
central blood volume, and provides a well-accepted model to
study the effect of a volume challenge on kidney function.
Characteristic changes are atrial distension and increased cardiac
output [3, 4], followed by progressive suppression of renal vascu-
lar resistance and elevation of renal blood flow 4—7]. Suppression
of sympathetic activity, apparent from decreased plasma flora-
drenaline levels [8, 9] and muscle sympathetic nerve activity [10],
probably plays a role in these changes.
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Whether centrally released opioids play a role as modulators of
the renal response to HOT has not been studied. Likelyhood for
such a role follows from the fact that HO! activates the afferents
of the cardiopulmonary baroreflex, which discharge into the
vasomotor centers of the brain stem, where opioid containing
neurons are abundant [11]. It has been demonstrated that HO! in
healthy humans is followed by sustained elevation of plasma
methenkephalin and suppression of -endorphin [12]. In a num-
ber of studies [4, 6, 13], but not in all [2], HO! was accompanied
by a decrease in blood pressure, which is remarkable since this
cannot be considered as the logical consequence of volume
expansion. In fact, this would suggest sympathetic suppression in
excess of the normal response to arterial baroreflex activation.
Possibly opioids released during HO! amplify the sympathetic
suppression. Indeed, it has been found that administration of a
metenkephalin analogue in humans is associated with a decrease
in blood pressure [14].
If it is true that centrally released opioids potentiate the
hemodynamic effects of HOI, one could expect that naloxone, a
potent opioid peptide antagonist [15], could attenuate the re-
sponse to HO!. Therefore, we studied the effect of HO! on renal
hemodynamics and blood pressure in healthy humans without and
with concomitant administration of naloxone.
Methods
General
Studies were carried out in six healthy subjects (3 male, 3
female) mean age 23 years (range 20 to 25 years), after informed
consent had been obtained. All subjects took a a diet containing
150 mmol Na for two periods of seven days, separated by an
interval of one or two weeks. Adherence to the diet was moni-
tored from 24-hour urine collections. All subjects underwent four
clearance studies, which were carried out on days 5 and 7 of each
diet period. The protocol was approved by the Hospital Ethical
Committee for Studies in Humans.
Clearance experiment
Clearance studies were performed in the morning after an
overnight fast, and with the subjects in the seated position in a
room with constant air temperature (29°C). Starting at 8 a.m. the
subjects ingested 250 ml tap water each half hour to ensure
adequate urine flow. Antecubital arm veins were cannulated
bilaterally for infusions and blood sampling. At 9 a,m. a priming
dose of a solution containing 2.5% inulin, to measure glomerular
filtration rate (GFR) and 2.5% para-aminohippurate (PAH) to
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measure estimated renal plasma flow (ERPF) was administered,
followed by a continuous infusion of this solution throughout the
remainder of the experiment. After at least one hour equilibra-
tion, three 30-minute urine collections were made (baseline) by
spontaneous voiding, and blood samples taken halfway through
each urine collection period. Subsequently, clearance measure-
ments were continued for another three hours, while the subjects
either remained seated in air, or were immersed in water (35°C)
up to the neck. In the water tank, the subjects remained seated,
with their forearms above the water, resting on a cradle. Through-
out the experiments blood pressure and heart rate were recorded
at 10 minute intervals with an automatic oscillometer device
(Omega 1000, in vivo Research Laboratory, Tulsa, OK, USA), the
pressure cuff being kept at heart level.
Study design
Each subject underwent two clearance experiments while
seated in air, and two clearance experiments while undergoing
water immersion. In either two conditions one experiment was
performed during naloxone administration, and the other during
placebo infusion. Naloxone or placebo was started after comple-
tion of the baseline collections. Naloxone was given as bolus of 0.1
mg/kg, followed by a maintenance infusion of 0.1 mglkg/hr,
suspended in saline, throughout the remainder of the experiment.
The total amount of saline infused throughout each experiment
was 1 ml/kg. For placebo an equal amount of saline was infused.
The order of the experiments was randomized, and the subjects
were blinded for administration of naloxone or placebo.
This design led to the following set of data: (1) time-control
data (seated in air during placebo); (2) effect of naloxone alone
(baseline data, followed by naloxone administration while seated
in air); (3) effect of water immersion (baseline data, followed by
water immersion during placebo infusion); (4) effect of simulta-
neous water immersion and naloxone administration (baseline
data, followed by water immersion and concomitant naloxone
infusion).
Analytical techniques
Blood and urine samples were analyzed for sodium and potas-
sium (flame photometry), inulin [161 and PAH [171. Blood
samples drawn during the final baseline period, and at 60, 120 and
180 minutes of the test, were also analyzed for plasma renin
activity (PRA), aldosterone, atrial natriuretic peptide (ANP), and
catecholamines. PRA, aldosterone and ANP were determined by
standard radioimmunoassays [18], and catecholamines by high
performance liquid chromatography with fluorimetric detection
[19].
Calculations, statistical analysis
Mean arterial pressure was calculated from the sum of one-
third of the systolic pressure and two-thirds of the diastolic
pressure. Renal blood flow was calculated by dividing ERPF by
[1-packed cell volume], and renal vascular resistance was calcu-
lated by dividing mean arterial pressure by renal blood flow.
Clearance data are presented at hourly intervals, calculated
from two consecutive 30-minute collections. Values are given as
means standard error. PRA and aldosterone were analyzed
after logarithmic transformation. Statistical analysis was per-
formed by repeated measures analysis of variance with head-out
immersion, and naloxone infusion as independent variables.
Table 1. Effect of naloxone on blood pressure and hormones
Baseline 0—60 mm 60—120 mm 120—180 mm
HR, bpm
time control 64 2 66 2 67 2 68 2
naloxonea 62 2 65 1 65 2 64 1
MAP, mm Hg
time control 89 2 88 2 89 2 88 2
naloxone 90 1 87 1 88 2 89 2
PRA, final.
liter' sec —
time control 661 129 741 125 912 96 912 107
naloxone 724 94 851 143 832 108 871 112
Aldosterone,
pmol liter'
time control 733 145 589 84 589 76 562 126
naloxone 794 123 977 178 646 53 537 49
ANP, pmolliter'
timecontrol 8±1 7±1 8±1 8±1
naloxone 6±1 6±1 7±1 6±1
NA, nmol
liter'
time control 1.21 0.21 1.16 0.16 1.08 0.10 1.05 0.18
naloxone 0.90 0.15 0.80 0.12 0.88 0.10 0.92 0.11
A, nmol . liter1
time control 0.10 0.03 0.11 0.03 0.13 0.04 0.13 0.03
naloxone 0.09 0.03 0.19 0.08 0.16 0.05 0.17 0.05
Abbreviations are: HR, heart rate; bpm, beats per minute; MAP, mean
arterial pressure; PRA, plasma renin activity; ANP, atrial natriuretic
peptide; NA, noradrenalin; A, adrenalin. Values are means SEM. There
were no significant changes over time, and no difference with and without
naloxone.
a In the naloxone experiment naloxone was started after the baseline
collections
When the variance ratios reached statistical significance, the
difference between the means were analyzed at 1% and 5%
significance levels by the least significant difference test. Differ-
ences in baseline values were tested by means of a paired t-test.
Results
Baseline data
Mean 24-hour sodium excretion prior to the four clearance
studies were not different: 135 11 mmol (time control), 130
9 mmol (naloxone administration only), 143 ii mmol (water
immersion) and 127 6 mmol (simultaneous water immersion
and naloxone administration). Baseline data for hemodynamics,
plasma hormones, and renal function are presented in the first
columns of Tables 1 through 4. No difference in baseline param-
eters existed between any of the four experiments. No side effects
occurred during the experiments with naloxone, of which the
results are described below.
Time control data, and effect of naloxone
In the time control experiment (Tables 1 and 2), no significant
changes were found in blood pressure, hormones and renal
function, except for urinary excretion of sodium and potassium,
which decreased consistently. Naloxone had no effect on these
parameters, and the time effect on sodium and potassium excre-
tion was undisturbed.
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Baseline 0—60 mm 60—120 mm 120—180 mm
GFR, ml- min'
time control 95 5 93 4 95 4 93 4
naloxonea 96 5 93 4 93 4 94 3
ERPF, ml- min'
time control 541 34 535 34 534 36 522 32
naloxone 539 28 507 23 527 24 530 29
FF, %
time control 17.7 0.8 17.8 1.2 18.2 1.0 18.3 1.0
naloxone 17.9 0.6 18.4 0.8 17.7 0.3 18.0 0.9
RBF, m1 min1
time control 935 48 913 49 898 46 865 39
naloxone 950 38 880 31 901 28 896 39
RVR, mm Hg
mm liter'
time control 96 6 98 6 101 7 103 6
naloxone 96 5 100 5 98 4 101 6
UNaV, iunolliter'
time control 76 18 52 12 45 10 43 7
naloxone 76 7 49 2 50 6 46 3
UKV, pmolliter'
time control 68 8 65 9 52 4 41 3'
naloxone 79 10 63 8 58 7 58 7"
Abbreviations are: GFR, glomerular filtration rate; ERPF, estimated
renal plasma flow; FF, filtration fraction; RBF, renal blood flow; RVR,
renal vascular resistance; UNaV, urinary sodium excretion; and UKV,
urinary potassium excretion. Values are means SEM.
In the naloxone experiment naloxone was started after the baseline
collections
bp < 0.05
Water immersion, and effect of naloxone
Water immersion was followed by a significant fall in blood
pressure, in the absence of reflex tachycardia (Table 3). This was
associated with profound and significant suppression of PRA,
aldosterone and noradrenalin, whereas plasma adrenalin re-
mained unchanged. Plasma ANP was stimulated significantly.
Both GFR and ERPF increased significantly, but the increase of
the latter was more prominent, and filtration fraction decreased
(Table 4). Renal blood flow increased as well, and renal vascular
resistance decreased substantially, by 23 2%.
During concomitant administration of naloxone, water immer-
sion suppressed blood pressure, PRA, aldosterone and noradren-
aim to similar extent as observed in the absence of naloxone. The
stimulation of ANP tended to be less, but the difference with HOl
without naloxone administration was not significant. Plasma
adrenalin again remained unaltered. In contrast, however, GFR,
ERPF, and renal blood flow did not increase significantly. In
comparison to the changes found during water immersion alone,
this renal response was significantly different (P < 0.05). The
decrease in filtration fraction was not significant. Calculated renal
vascular resistance decreased by 15 1%, but this decrease was
significantly less than observed in the absence of naloxone (P <
0.05). The effect of water immersion of urinary sodium excretion
was not different during naloxone.
Discussion
The main finding of this study in healthy humans is that
naloxone attenuated the renal vasodilatory response to HOT. No
Baseline
0—60
mm
60—120 120—180
mm mm A
HR, bpm
placebo
naloxone
62 265 2 65 265 2 66 1 66 168 1 67 2 NS
MAP, mm Hg
placebo
naloxone
89 389 2 75 2hd77 1b 76 l' 76 l"'77 1" 76 1bd NS
PP.A, Jinolliter' sec'
placebo
naloxone
813 106
851 51
437 57513 48 269 49 219 43347 41 316 45a NS
Aldosterone,
pmol - liter'
placebo
naloxone
724 131
676 151
339 40c1
490 76
191 27e 162 13282 20 234 l4 NS
AMP, pmol
liter1
placebo
naloxone
7 18 1 1311 2 17 3 16 312 1 13 2 NS
NA, nmol
liter'
placebo
naloxone
1.09 0.21
0.86 0.12
0.69 0.09
0.53 0.08
0.60 0.08 0.55 0.08
0.59 0.11 0.53 0.11
NS
A, nmol
liter'
placebo
naloxone
0.15 0.03
0.08 0.02
0.09 0.02
0.10 0.02
0.10 0.03 0.12 0.03
0.11 0.03 0.11 0.02
NS
Abbreviations are: HR, heart rate; bpm, beats per minute; MAP, mean
arterial pressure; PRA, plasma renin activity; ANP, atrial natriuretic
peptide; NA, noradrenalin; A, adrenalin. Values are means SEM.
a In the naloxone experiment naloxone was started after the baseline
collections
b P < o•5, c P < 0.01 compared to baseline.
d P < 0.05, P < 0.01 compared to corresponding time control or
naloxone without water immersion (Table 1). Column A indicates whether
the response to water immersion during naloxone differed from the
response to water immersion during placebo.
effect was found on the blood pressure response and natriuretic
response to HOT, nor on basal renal hemodynamics.
The involvement of endogenous opioids in cardiovascular con-
trol has been the subject of multiple studies. Many of these made
use of naloxone, which is a potent antagonist of s-type opioid
receptors [15]. Following from these studies, there is general
agreement that in basal conditions the opioid system has a minor
role in cardiovascular regulation [20, 21]. The present study
confirms this notion, and adds that this also holds true for the
control of renal hemodynamics.
Opioid cardiovascular control becomes significant in conditions
of stress and sympathetic activation. Intravenous naloxone has
been shown to increase blood pressure during hypotension caused
by hemorrhage in conscious rats [22], rabbits [23, 24] and baboons
[25], indicating that endogenous opioids blunt activation of the
baroreflex [21]. In humans, the cardiovascular effects of naloxone
have been studied in various situations of sympathetic activation,
such as septic shock [26, 27], hypotension induced by nitroprus-
side [28, 29] or lower body negative pressure [30—32], dynamic
[20, 33, 34] and static exercise [29, 35, 36], and cold exposure [29,
31, 37, 38]. Depending upon the circumstances, naloxone was
found to enhance the increase in blood pressure [26, 27, 37], heart
Table 2. Effect of naloxone on renal function Table 3. Effect of naloxone on blood pressure and humoral response to
water immersion
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Table 4. Effect of naloxone on renal response to water immersion
Baseline
0—60
mm
60—120
mm
120—180
mm A
GFR,
ml' min'
placebo
naloxoneC
94 597 3 96 495 2 99 5°97 3 102 5°97 3 P < 0.05
ERPF,
ml' mm - 1
placebo
naloxone
529 30
534 29
557 36
542 24
576 35b
559 32
616 35°
569 29
p < 0.05
FF, %
placebo
naloxone
18.6 1.0
18.3 0.4
17.3 0.5
17.6 0.5
17.1 0.6"
17.6 0.7
16.7 0.6'
17.3 0.7
NS
RBF,
ml' min'
placebo
naloxone
907 47
923 45
939 57
921 38
956 54
932 47
1006 53b
933 44
P < 0.05
RVR, mm Hg'
mm liter1
placebo
naloxone
99 698 6 81 4"'84 3 81 5CC84 5hd 77 5"83 5"° p < 0.05
UNaV,
iinol ' liter'
placebo
naloxone
60 9
71 9 85 12"78 18" 115 22CC100 l3he 157 30CC144 22 NS
UKV,
pinol ' liter'
placebo
naloxone
68 11
66 14
90 12
65 12
82 6"
86 20"
65 5
73 11
NS
Abbreviations are: GFR, glomerular filtration rate; ERPF, estimated
renal plasma flow; FF, filtration fraction; RBF, renal blood flow; RVR,
renal vascular resistance; UNCV, urinary sodium excretion; and UKV,
urinary potassium excretion. Values are means SEM.
C In the naloxone experiment naloxone was started after the baseline
collections.
"p < 0.05; "P < 0.01 compared to baseline.
"P < 0.05; "P < 0.01 compared to corresponding time control or
naloxone without water immersion (Table 2). Column A indicates whether
the response to water immersion during naloxone differed from the
response to water immersion during placebo.
rate [20, 28, 37], catecholamines [331, peripheral vascular resis-
tance [31, 321, and muscle nerve sympathetic activity [29, 31, 321,
however, for each criterium studied often either no or no signif-
icant effects were found in other studies [29—31, 33—36, 38].
We currently studied the effect of naloxone on the cardiovas-
cular response, and the renal hemodynamic response in particular
to HOl, which represents, by contrast, a model of sympathetic
activation. Sympathetic deactivation by HOl in the present
study was confirmed by the consistent fall in plasma noradrenaline
levels, by the blood pressure decrease in the absence of tachycar-
dia, and by the renal vasodilation, changes found previously by
others [4, 5, 8, 9, 12, 13] and ourselves [6, 7, 18]. The accompa-
flying increase in glomerular filtration rate was also comparable to
that found previously, although this change often failed to reach
significance [7, 181. Interestingly, it appeared that naloxone atten-
uated the renal vasodilatory effect and prevented the increase in
glomerular filtration rate, but not the other effects of HOl.
We are not aware of previous studies addressing the effect of
opioid antagonists on the response to HO!. In fact, only few data
are available on opioid cardiovascular control in situations involv-
ing sympathetic deactivation. Naloxone was shown to enhance the
bradycardiac response to blood pressure elevation by phenyleph-
rifle infusion in conscious rats [39], whereas the opposite was
found in anesthetized dogs [40] and conscious rabbits [411. Such
data in humans are not available, but it has been demonstrated
that naloxone can prevent the physiological blood pressure fall
during sleep [42], and post-exercise hypotension [43] or peripheral
vasodilation [44]. Furthermore, the hypotensive effect of clonidine,
which also acts by decreasing sympathetic outflow [45], is attenu-
ated by naloxone [46], although this is not a universal finding [47].
Altogether, these data suggest that endogenous opioids could
indeed enhance sympathetic deactivation following HOI.
The response of mean arterial pressure to HO! varies from no
change [48, 49] to a decrease of about 8 mm Hg [4, 6, 18] or even
of 13 mm Hg, as found presently and in one previous study by
others [13]. The reason for this variation is not clear, since
reported bath water temperatures, immersion depth or duration
were not different in these studies. More importantly, naloxone
did not diminish this hypotensive response. This is remarkable in
view of the above-mentioned properties of naloxone, and in view
of the present finding that naloxone attenuated the renal vasodi-
latory response to HO!. Clearly, however, naloxone did not cause
global attenuation of sympathetic suppression, since the decrease
in plasma noradrenaline caused by HO! was also not affected. A
differential effect of naloxone on the response of renal versus
other vascular beds to sympathetic deactivation has not been
reported before. This suggests a differential control of sympa-
thetic tone of renal vasculature and systemic resistance vessels.
Topographic or functional dissociation of brain stem vasomotor
neurons controlling sympathetic output to the kidney and the
systemic resistance vessels has indeed been found in cats [50, 51]
and rabbits [52, 53]. However, it is unknown whether this disso-
ciation also implies differential control by endogenous opioids, or
different accessibility for intravenously administered naloxone.
We only applied one dosage of naloxone, and its is possible that
a higher dosage naloxone would also have diminished the blood
pressure decrease following HOl. However, the dosage applied
presently was similar to that used in the above-mentioned studies
in which naloxone inhibited the blood pressure decrease associ-
ated with sympathetic deactivation [37, 42, 43].
Remarkably little data are available on the control of endoge-
nous opioids of renal hemodynamics. In conscious rabbits nalox-
one had no effect on the increased renal nerve activity during the
sympathoexcitatory phase of progressive hemorrhage [54, 551,
however, prevented suppression of renal nerve activity during the
sympathoinhibitory phase [23, 54, 551. Resting renal blood flow or
renal sympathetic activity remained unaffected by naloxone in
conscious rats [56] and anesthetized rabbits [57]. These observa-
tions are in agreement with our finding that naloxone attenuated
the renal vasodilation following HO!, hut had no effect on basal
renal hemodynamics. We are not aware of such data in other
species.
Sodium excretion increased by 2.5-fold in the third hour of
HOT. A two- to threefold increase was previously found by others
[5, 48, 49, 581 and ourselves [18] in healthy subjects undergoing a
similar period of HO!, and starting from a comparable basal
sodium excretion. In contrast to the attenuated renal vasodilation,
naloxone did not disturb the natriuretic response to HOl. This is
the more remarkable, since naloxone also tended to attenuate the
increase in plasma ANP, an effect found previously by others [59].
A similar dissociation appeared in an other study, in which we
showed that treatment with a prostaglandin synthesis inhibitor for
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one week completely prevented the increase in ERPF following
HOT, but did not diminish its natriuretic effect [7]. In a previous
study in which we compared the actions of HO! and atrial
natriuretic peptide infusion [181, we suggested that maximal renal
vasodilation during HO! may be crucial for its natriuretic effect.
Apparently, that is not the case. Notably however, naloxone did
not prevent all renal vasodilation. Residual renal vasodilation
conceivably facilitated sodium excretion caused by other factors
such as HOT-induced suppression of plasma renin and aldoste-
rone, which was not impaired by naloxone. A natriuretic effect of
naloxone itself is unlikely, since naloxone alone did not affect
sodium excretion.
Little is known on the role of endogenous opioids in sodium
balance. In contrast to our study, injection of morphine into the
cerebral ventricle in rats has been shown to decrease sodium
excretion without changing renal hemodynamics [56]. The same
has been found after systemic administration of morphine [601, an
effect requiring uptake by the central nervous system [61] and an
intact renal nerve [62]. However, this does not necessarily imply
such a role for endogenously released opioids, since intracerebral
administration of opioids may cause opposite effects depending
upon the site of injection [11].
Finally, we should consider that the differential effects of
naloxone on renal versus systemic hemodynamics was related to a
specific peripheral action of naloxone. This option, however, is
unlikely. The renal cortex probably has opioid receptors of the
K-type [63]. These receptors, of which the function is unknown,
have a low affinity for naloxone. In this regard, it may be relevant
that in humans undergoing HOl, sustained elevation of plasma
levels of methenkephalin and suppression of 13-endorphin have
been demonstrated [12]. Studies in various animals [57, 64—66]
and humans [14] have shown that methenkephalin, when admin-
istered intravenously, lowers blood pressure and heart rate, effects
which can be prevented by coadministration of naloxone [57, 64,
66]. Systemically released metenkephalin probably lowers blood
pressure through an action on sympathetic ganglia [65]. There-
fore, the option that naloxone in the present setting mainly
interacted with peripheral opioid mechanisms cannot explain the
observed differential effects on blood pressure and renal hemo-
dynamics.
In summary, we found that naloxone, in a dosage that did not
affect baseline renal or systemic hemodynamics, diminished the
renal vasorelaxation but not the systemic arterial pressure de-
crease caused by water immersion. This is the first indication that
endogenous opioids are indeed involved in the vasomotor re-
sponse to water immersion. Apparently, this opioid involvement
particularly concerns the kidney.
Acknowledgment
This study was supported by the Dutch Kidney Foundation, grant
C91 .1108. We gratefully acknowledge our department of physiotherapy
(head P.J.M. Helders, M.D.) for giving us the opportunity to use the
immersion tank, and F. Boomsma, Ph.D., Department of Internal Medi-
cine I, University Hospital Rotterdam, The Netherlands, for the determi-
nation of the catecholamjnes.
Reprint requests to HA Koomans, MD., Department of Nephrology and
Hypertension, University Hospital Utrecht, Room F03.226, P.O. Box 85500,
3508 GA Utrecht, The Netherlands.
1. VAN TILBORG KA, RABELINK Ti, vA.N RIJN HiM, BOOMSMA F, Koo-
MANS HA: Arterial baroreflex control of renal hemodynamics in
humans. Circulation 90:1883—1890, 1994
2. EPSTEIN M: Renal effects of head-out water immersion in humans: A
15-year update. Physiol Rev 72:563—621, 1992
3. ARBORELIUS M, BALLDIN UI, LIlA B, LUNDGREN CEG: Hemody-
namic changes in man during immersion with the head above water.
Aerosp Med 43:592—598, 1972
4. MYERS BD, PETERSON C, MOLIN C, TOMLANOVICH Si, NEWTON LD,
NITRIN R, SANDLER H, MURAB F: Role of cardiac atria in the human
renal response to changing plasma volume. Am J Physiol 254:F562—
F573, 1988
5. CoRuzzi P, BIGGI A, MUSIARI L, RAVANETFI C, N0vARINI A: Renal
hemodynamics and natriuresis during water immersion in normal
humans. Pfiugers Arch 407:638—642, 1986
6. RABELINK TJ, VAN TILBORG KA, HENE RJ, KOOMANS HA: Natriuretic
response to head-out water immersion in humans with recent kidney
transplants. Clin Sci 85:471—477, 1993
7. RABELINK TJ, K0OMAN5 HA, DORHOUT MEES EJ: Role of prostag-
landins in natriuresis of head-out water immersion in humans. Clin Sci
80:481—488, 1991
8. KRISHNA GG, DANOWTCH GM, SOWERS JR: Catecholamine responses
to central volume expansion produced by head-out water immersion
and saline infusion. J Clin Endocnnol Metab 56:998—1002, 1983
9. GROSSMAN E, GOLDSTEIN DS, HOFFMAN A, WACKS !R, EPSTEIN M:
Effects of water immersion on sympathoadrenal and dopa-dopamine
systems in humans. Am J Physiol 262:R993—R999, 1992
10. SAITO M, MAN0 T, IwASE S, KOGA K, MATSUKAWA T: Sympathetic
nervous responses in man to weightlessness simulated by head-out
water immersion, in Biological Sciences in Space, WATANABE S,
MITARAI G, MORI S, Tokyo, Myo Research, 1985, pp 85—92
11. HOLADAY JW: Cardiovascular effects of endogenous opiate systems.
Ann Rev Pharmacol Toxicol 23:541—594, 1983
12. CoRuzzl P, RAVANETrI C, MUSIARI L, BIGGI A, VESCOVI PP, NovA-
RINI A: Circulating opioid peptides during water immersion in normal
man. Clin Sci 74:133—136, 1988
13. CORRUZI P, NovARINI AA, BIGGI A, LAZZERONI E, Mu5IARI L,
RAVANETFI C, TAGuviNi S, BORGHETFI A: Low pressure receptor
activity and exaggerated natriuresis in essential hypertension. Nephron
40:309—315, 1985
14. RUBIN PC, MCLEAN K, Bsc, REID JL: Endogenous opioids and
baroreflex control in humans. Hypertension 5:535—538, 1983
15. GOLDSTEIN A, NAIDU A: Multiple opioid receptors: ligand selectivity
profiles and binding site signatures. Molec Phannacol 36:265—272,
1989
16. HEYROWSKI A: A new method for determination inulin in plasma and
urine. Clin Chim Acta 1:470—474, 1957
17. WAUGH WH, BEALL PT: Simplified measurement of p-aminohippu-
rate and other arylamines in plasma and urine. Kidney mt 5:429—436,
1974
18. RABELINK AJ, KooMA.Ns HA, BOER P, GAILLARD CA, DORHOUT
MEES EJ: Role of ANP in natriuresis of head-out water immersion in
humans. Am J Physiol 257:F375—F382, 1989
19. HOORN FAJ, VAN DER, BOOMSMA F, MAN IN 'T VELD AJ, SCHALEKAMP
MADH: Determination of catecholamines in human plasma by
high-performance liquid chromatography: Comparison between a new
method with fluorescence detection and an established method with
electrochemical detection. J Chromatogr 487:17—28, 1989
20. MCMURRAY RG, NEWBOULD F, BOULOUX P, BESSER GM, GROSSMAN
A: High-dose naloxone modifies cardiovascular and neuroendocrine
function in ambulant subjects. Psychoneuroendocrinology 16:447-455,
1991
21. SCHADT JC, LUDBROOK J: Hemodynamic and neurohumoral re-
sponses to acute hypovolemia in conscious mammals. Am J Physiol
260:H305—H318, 1991
22. BENNE1-r T, GARDINER SM: The influence of naloxone on haemor-
rhagic hypotension in Brattleboro rats. JPhysiol (Lend) 332:69P—70P,
1982
23. MORITA H, NIsHIDA Y, MOTOCHIGAWA H, UEMURA N, HosoMi H,
VATNER SF: Opiate receptor-mediated decrease in renal nerve activity
References
van Tilborg et al: Opioid role in response to water immersion 865
during hypotensive hemorrhage in conscious rabbits. Circ Res 63:165—
172, 1988
24. RUYrER PC, POTOCNIK SJ, LUDBROOK J: Factors influencing the
effects of intravenous naloxone on arterial pressure and heart rate
after haemorrhage in the conscious rabbit. Clin Exp Pharmacol Physiol
13:383—397, 1986
25. GOLANOVEV, CFIERKOVICH GM, SUCHKOV VV: Effect of naloxone in
hypotension induced by acute blood loss in baboons (Papio hama-
dryas). Bull Exp Biol Med 96:1428—1431, 1993
26. HUGHES GS: Naloxone and methyiprednisolone sodium succinate
enhance sympathomedullaiy discharge in patients with septic shock.
Life Sci 35:2319—2326, 1984
27. ROBERTS DE, DOBSON KE, HAIL KW, LIGHT RB: Effects of pro-
longed naloxone infusion in septic shock. Lancet 2:699—702, 1988
28. RUBIN PC, MCLEAN K, REID JL: Endogenous opioids modulate
central nervous system blood pressure control in man. Clin Sci
63:331S—333S, 1982
29. FARRELL PA, EBERT TJ, KAMPINE JP: Naloxone augments muscle
sympathetic nerve activity during isometric exercise in humans. Am J
Physiol 260:E379—E388, 1991
30. FOLDAGER N, BONDE-PETERSEN F: Human cardiovascular reactions to
simulated hypovolemia, modified by the opiate antagonist naloxone.
EurJApplPhysiol 57:507—513, 1988
31. SCH0BEL HP, OREN RM, MARK AL, FERGUSON DW: Naloxone
potentiates cardiopulmonary baroreflex sympathetic control in normal
humans. Circ Res 70:172—183, 1992
32. SMITH ML, CARLSON MD, THAMES MD: Naloxone does not prevent
vasovagal syncope during simulated orthostasis in humans. J Auto-
nomic Nere Syst 45:1—9, 1993
33. GROSSMAN A, BouLoux P, PRICE P, DRURY PL, LAM KSL, TURNER T,
THOMAS J, BESSER GM, SUTTON J: The role of opioid peptides in the
hormonal responses to acute exercise in man. Clin Sci 67:483—491,
1984
34. STAESSEN J, FIOCCHI R, BOUILLON R, FAGARD R, HESPEL P, LIJNEN P,
MOERMAN E, AMERY A: Effects of opioid antagonism on the haemo-
dynamic and hormonal responses to exercise. Clin Sci 75:293—300,
1988
35. LAM KSL, GROSSMAN A, BOULOUX P, DRURY PL, BESSER GM: Effect
of an opiate antagonist on the responses of circulating catecholamines
and the renin-aldosterone system to acute sympathetic stimulation by
hand-grip in man. Acta Endocrinol 111:252—257, 1986
36. VICI'OR RG, PRY0R SL, SECHER NH, MITCHELL JH: Effects of partial
neuromuscular blockade on sympathetic nerve responses to static
exercise in humans. Clin Res 65:468—476, 1989
37. BOULOUX P, GROSSMAN A, AL-DAMLUJI S, BAILEY T, BESSER M:
Enhancement of the sympathoadrenal response to the cold-pressor
test by naloxone in man. Clin Sci 69:365—368, 1985
38. BOULOUXPMG, NEWBOULD E, CAUSON R, PERRY L, REES LH,
BESSER GM, GROSSMAN A: Differential effect of high-dose naloxone
on the plasma adrenaline response to the cold-pressor test. Clin Sd
76:625—630, 1989
39. SZILAGYI JE: Endogenous opiate modulation of baroreflexes in
normotensive and hypertensive rats. Am J Physiol 255:H987—H991,
1988
40. SZILAGYI JE: Opioid modulation of baroreceptor reflex sensitivity in
dogs. AmJ Physiol 252:H733-H737, 1987
41. WEKSLER-ZANGEN S, CHOREV M, WEINSTOCK M: Contrasting influ-
ences of central and peripheral opioids on cardiac baroreflex sensi-
tivity in rabbits. J Cardiovasc Pharmacol 20:688—693, 1992
42. RUBIN P, BLASCHKE TF, GLJILLEMINAULT C: Effect of naloxone, a
specific opioid inhibitor, on blood pressure fall during sleep. Circula-
tion 63:117—121, 1981
43. BOONE JB, LEVINE M, FLYNN MG, PIZZA FX, KUBITZ ER, ANDRES
FF: Opioid receptor modulation of postexercise hypotension. Med Sci
Sports Exerc 240:1108—1113, 1992
44. HARA K, FLORAS JS: Effects of naloxone on hemodynamics and
sympathetic activity after exercise. JAppi Physiol 73:2028—2035, 1992
45. Muzi NM, GOFF DR, KAMPINE JP, ROERIG DL, EBERT TJ: Clonidine
reduces sympathetic activity but maintains baroreflex responses in
normotensive humans. Anesthesiology 77:864—871, 1992
46. FARSANG C, KAP0csI J, JUHASZ I, KUNOS U: Possible involvement of
an endogenous opioid in the antihypertensive effect of clonidine in
patients with essential hypertension. Circulation 66:1268—1272, 1982
47. PEDRINELLI R, BERNINI GP, SALvETrI A: Naloxone does not modify
the hemodynamic and neuroendocrine effects of clonidine in normal
humans. J Cardiovasc Pharmacol 7:953—957, 1985
48. NORSK P, BONDE-PETERSEN F, WARBERO J: Arginine vasopressine,
circulation, and kidney during graded water immersion in humans. J
AppI Physiol 61:565—574, 1986
49. SHIRAKJ K, KONDA N, SAGAWA S, CLAYBAUGH JR, HONG SK:
Cardiorenal-endocrine responses to head-out immersion at night. J
AppI Physiol 60:176—183, 1986
50. LOVICK TA: Differential control of cardiac and vasomotor activity by
neurones in nucleus paragigantocellularis lateralis in the cat. J Physiol
389:23—35, 1987
51. MCALLEN RM, DAMPNEY RAL: Vasomotor neurons in the rostral
ventrolateral medulla are organized topographically with respect to
type of vascular bed but not body region. Neurosci Lett 110:91—96,
1990
52. HASSER EM, NELSON DO, HAYW000 JR, BISHOP VS: Inhibition of
renal sympathetic nervous activity by area postrema stimulation in
rabbits.Am J Physiol 253:H91—H99, 1987
53. BELULI DJ, WEAVER LC: Differential control of renal and splenic
nerves without medullasy topography. Am J Physiol 260:H1072—
H1079, 1991
54. BURKE SL, DORWARD PK: Influence of endogenous opiates and
cardiac afferents on renal nerve activity during haemorrhage in
conscious rabbits. J Physiol (Lond) 402:9—27, 1988
55. LUDEROOK J, RUTFER PC: Effect of naloxone on haemodynamic
responses to acute blood loss in unanaesthetized rabbits. J Physiol
Lond 400:1—14, 1988
56. DANESHS,WALKERLA:Effects of central administration of morphine
on renal function in conscious rats. J Pharmacol Exp Ther 244:640—
645, 1987
57. EULIE PJ, RHEE HM, LAUGHLIN MH: Effects of Met5]enkephalin on
regional blood flow and vascular resistance in rabbits. EurJPharmacol
137:25—31, 1987
58. EPSTEIN M, PRESTON 5, WEITZMAN RE: Isoosmotic central blood
volume expansion suppresses plasma arginine vasopressine in normal
man. J Clin Endocrinol Metab 52:256—262, 1981
59. WIDERA W, KOKOT F, WIECEK A: Do opioid receptors participate in
the regulation of atrial natriuretic peptide (AMP) secretion in hyper-
tensive patients? Clin Nephrol 38:209—213, 1992
60. WALKER LA, MURPHY JC: Antinatriuretic effect of acute morphine
administration in conscious rats. J Pharmacol Exp Ther 229:404—408,
1984
61. HUIDOBRO-TORO JP, HUIDOBRO F: Central effects of morphine,
levorphanol, (-)-methadone, and the opioid-Iike peptides J3-endor-
phine and D-alanine-methionine enkephalinamide on urine outflow
and electrolytes. J Pharmacol Exp Ther 217:570—585, 1981
62. WALKER LA, MURPHY JC: Effect of renal denervation on the antina-
triuretic response to morphine administration in conscious rats. J
PharmacolExp Ther 237:799—802, 1985
63. QUIRI0N R, FINKEL MS, MENDELSOHN FAO, ZAMIR N: Localization
of opiate binding sites in kidney and adrenal gland of the rat. Life Sci
33:299—302, 1983
64. WEI ET, LEE A, CHANG JK: Cardiovascular effects of peptides related
to the enkephalins and 13-casomorphin. Life Sci 26:1517—1522, 1980
65. CAFFREY JL, GU H, BARRON BA, GAUGL JF: Enkephalin lowers
vascular resistance in dog hindlimb via a peripheral nonlimb site. Am
J Physiol 260:H386—H392, 1991
66. JANG W, SCHADT JC, GADDIS RR: Peripheral opioidergic mechanisms
do not mediate naloxone's pressor effect in the conscious rabbit. Circ
Shock 39:121—127, 1993
